Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NEXOBRID

(NexoBrid)

Small molecule

VVericel Corporation

0

Indications

3

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

Completed·MMediWound Ltd·Phase 3·NCT02148705·175 enrolled

A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Completed·MMediWound Ltd·Phase 3·NCT02278718·145 enrolled

Treatment1 trial

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Approved for marketing·MMediWound Ltd··NCT04040660

Regulatory

FDA Approval Timeline[3]

Dec 28, 2022

NEXOBRID

BLA BLA761192

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NexoBrid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NexoBrid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (BLA BLA761192). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Vericel Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: VVericel Corporation

Related News